84547-84-2

Basic information

• Product Name: 4-bromo-1-methylpyrazole-3-carboxy acid
• Synonyms: 4-bromo-1-methyl-1H-pyrazole-5-carboxylic acid(SALTDATA: FREE);4-Bromo-2-methylpyrazole-3-carboxylic acid;1-Methyl-4-bromopyrazole-5-carboxylic acid;4-bromo-1-methylpyrazole-3-carboxy acid
• CAS NO: 84547-84-2
• Molecular Formula: C₅H₅BrN₂O₂
• Molecular Weight: 205.01
• Mol File: 84547-84-2.mol

Chemical Properties

• Melting Point: 235-236 °C
• Boiling Point: 347.4 °C at 760 mmHg
• Flash Point: 163.9 °C
• Appearance: /
• Density: 1.93 g/cm³
• Vapor Pressure: 2.03E-05mmHg at 25°C
• Refractive Index: 1.658
• Storage Temp.: 2-8°C
• PKA: 1.75±0.37(Predicted)
• CAS DataBase Reference: 4-bromo-1-methylpyrazole-3-carboxy acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-1-methylpyrazole-3-carboxy acid(84547-84-2)
• EPA Substance Registry System: 4-bromo-1-methylpyrazole-3-carboxy acid(84547-84-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 84547-84-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-bromo-1-methylpyrazole-3-carboxylic acid is used as a synthetic intermediate for the preparation of various organic compounds. The presence of the bromine atom allows for further functionalization and modification of the molecule, making it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 4-bromo-1-methylpyrazole-3-carboxylic acid is used as a key component in the development of new drugs. The methyl and carboxylic acid groups can be utilized to enhance the compound's bioactivity, solubility, and pharmacokinetic properties, making it a promising candidate for the treatment of various diseases and disorders.
Used in Chemical Research:
4-bromo-1-methylpyrazole-3-carboxylic acid is also used as a research tool in chemical and biological studies. Its unique structure and functional groups make it an interesting subject for investigating reaction mechanisms, exploring new synthetic routes, and understanding the relationship between molecular structure and biological activity.

InChI:InChI=1/C5H5BrN2O2/c1-8-4(5(9)10)3(6)2-7-8/h2H,1H3,(H,9,10)

Upstream product

• 15803-02-8 4-bromo-1-methyl-1H-pyrazole 
• 591-51-5 phenyllithium 
• 5775-86-0 4-bromo-1,5-dimethyl-1H-pyrazole 
• 16034-46-1 1-methyl-1H-pyrazole-5-carboxylic acid 
• 694-31-5 1,5-dimethyl-1H-pyrazole 
• 13808-64-5 4-bromo-3-methyl-1H-pyrazole 
• 124-38-9 carbon dioxide 

Downstream Products

• 93703-04-9 4-(2-Methoxy-phenylamino)-2-methyl-2H-pyrazole-3-carboxylic acid 
• 93703-00-5 1-methyl-4-[(4-methylphenyl)amino]-1H-pyrazole-5-carboxylic acid 
• 93703-01-6 4-(4-Chloro-phenylamino)-2-methyl-2H-pyrazole-3-carboxylic acid 
• 93703-02-7 4-(4-Methoxy-phenylamino)-2-methyl-2H-pyrazole-3-carboxylic acid 
• 93703-03-8 1-methyl-4-(4-nitrophenylamino)pyrazole-5-carboxylic acid 
• 93703-05-0 1-methyl-4-(2-nitrophenylamino)pyrazole-5-carboxylic acid 
• 93702-99-9 2-Methyl-4-phenylamino-2H-pyrazole-3-carboxylic acid 
• 514816-42-3 4-bromo-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester 
• 1350323-53-3 4-{3-[(1S)-1-(2-Chloro-3-fluoro-6-methoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-1-methyl-1H-pyrazole-5-carboxamide 
• 1350323-54-4 (4-{3-[(1S)-1-(2-Chloro-3-fluoro-6-methoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-1-methyl-1H-pyrazol-5-yl)methanol 
• 1276056-83-7 (4-bromo-1-methyl-1H-pyrazol-5-yl)methanol 
• 1396007-83-2 4-bromo-2-methyl-2H-pyrazol-3-yl-carbamic acid (R)-1-phenyl-ethyl ester 

Relevant articles and documents

Compound for treatment on hepatitis B and use thereof

The invention relates to a compound for treatment on hepatitis B and a use thereof. Specifically, the invention discloses a compound as a HBV replication inhibitor having the structure shown in the formula (A), or its stereoisomer, tautomer, pharmaceutically acceptable salt, hydrate or solvate. The groups are detailed in the specification. The invention also relates a pharmaceutical composition containing the compound and a use thereof in treatment on hepatitis B.

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.